Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641226 | 1.00 | CYP2A6 (0.58) | CYP2A6AHRERN1HRH4NOS1 | |
| SCHEMBL4273824 | 0.85 | CYP2A6 (0.58) | CYP2A6AHRERN1HRH4NOS1 | |
| SCHEMBL17433388 | 0.84 | AHR (0.45) | CYP2A6AHRHRH4NOS1METAP2 | |
| SCHEMBL17422776 | 0.78 | CYP19A1 (0.45) | CYP2A6AHR | |
| SCHEMBL17422778 | 0.78 | CYP19A1 (0.45) | CYP2A6AHR | |
| SCHEMBL29955078 | 0.77 | CYP2A6 (0.58) | CYP2A6AHR | |
| SCHEMBL286843 | 0.77 | CYP2A6 (0.58) | CYP2A6AHRHRH4NOS1DYRK1A | |
| SCHEMBL5361224 | 0.77 | CYP2A6 (0.58) | CYP2A6PIM3 | |
| SCHEMBL2548885 | 0.77 | CYP2A6 (0.58) | CYP2A6AHR | |
| SCHEMBL29466343 | 0.77 | CYP2A6 (0.58) | CYP2A6PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4531849-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119604287-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| EP-3885342-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117800977-A | Preparation method and application of 2, 3-condensed quinazolinone compound | 桂林理工大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-101851237-B | spiro compounds, method for preparing same and application thereof | UNIV SOUTHERN MEDICAL | 2012-10-17 | — | — | CN | disclosed |
| WO-2012088038-A2 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088038-A2 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| CN-102432522-A | Preparation method of substituted indole-2-ketone compound | UNIV PLA 2ND MILITARY MEDICAL | 2012-05-02 | — | — | CN | disclosed |
| CN-102285909-A | Preparation method of benzpyrole-2-ketone compound | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011122815-A2 | NOVEL QUINOXALINE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2011-10-06 | — | — | WO | disclosed |
| CN-101851237-A | spiro compounds, method for preparing same and application thereof | UNIV SOUTHERN MEDICAL | 2010-10-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | CYP2A6 4274/4885AHR 3197/4885ERN1 1880/4885 |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | CYP2A6 2433/4885AHR 2489/4885ERN1 1490/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | CYP2A6 3973/4885AHR 3887/4885ERN1 2224/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CYP2A6 2433/4885AHR 2489/4885ERN1 1490/4885 |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI6, PADI2 | CYP2A6 1324/4885AHR 3195/4885ERN1 3008/4885 |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | MCHR1, MCHR2, MC1R | CYP2A6 1611/4885AHR 63/4885ERN1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.